January 25, 2016 9:30 AM | 1 min read |
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Analysts at Morgan Stanley downgraded American Express Company (NYSE: AXP) from Overweight to Equal-weight. The target price for American Express has been lowered from $88 to $64. American Express shares closed at $55.05 on Friday.Analysts at JP Morgan downgraded Potash Corporation of Saskatchewan (USA) (NYSE: POT) from Overweight to Neutral. Potash Corporation of Saskatchewan shares closed at $16.09 on Friday.Nomura downgraded
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
(NYSE: JPM) from Buy to Neutral. The target price for JPMorgan has been raised to $71. JPMorgan shares closed at $56.92 on Friday.BMO Capital downgraded Bristol-Myers Squibb Co (NYSE: BMY) from Outperform to Market Perform. Bristol-Myers Squibb shares closed at $64.41 on Friday. Analysts at Piper Jaffray downgraded Power Solutions International Inc (NASDAQ: PSIX) from Overweight to Neutral. Power Solutions shares closed at $14.52 on Friday.Analysts at Gabelli & Co downgraded Accuride Corporation (NYSE: ACW) from Buy to Hold. Accuride shares closed at $0.891 on Friday.Goldman Sachs downgraded Caterpillar Inc. (NYSE: CAT) from Neutral to Sell. Caterpillar shares closed at $60.99 on Friday.JMP Securities downgraded Toll Brothers Inc (NYSE: TOL) from Outperform to Market Perform. Toll Brothers shares closed at $28.21 on Friday.Analysts at Stifel Nicolaus downgraded Twitter Inc (NYSE: TWTR) from Buy to Hold. Twitter shares closed at $17.84 on Friday.Analysts at Chardan Capital downgraded Regeneron Pharmaceuticals Inc (NASDAQ: REGN) from Neutral to Sell. The target price for Regeneron Pharmaceuticals has been lowered from $525 to $400. Regeneron Pharmaceuticals shares closed at $482.99 on Friday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.